Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.
In addition to BCR, various rare fusion partners for the ABL1 gene have been reported in leukemia. We have identified the fusion gene SNX2-ABL1 in a pediatric case of acute lymphoblastic leukemia (ALL), which has only once previously been reported in an adult patient. Cytogenetic analysis detected this fusion gene arising from a t(5;9)(q22;q34) translocation. ALL cells carrying a SNX2-ABL1 fusion exhibited a BCR-ABL1+ ALL-like gene expression profile. The patient poorly responded to dasatinib but partially responded to imatinib. Treatment using tyrosine kinase inhibitors requires further investigation to optimize the genotype-based treatment stratification for patients with SNX2-ABL1 fusion.
Division of Pediatric Oncology, National Center for Child Health and Development, Setagaya-ku, Japan.
Aki
A
Masuzawa
Chikako
C
Kiyotani
Tomoo
T
Osumi
Yoko
Y
Shioda
Kazutoshi
K
Iijima
Osamu
O
Tomita
Kazuhiko
K
Nakabayashi
Keisuke
K
Oboki
Kazuki
K
Yasuda
Hiromi
H
Sakamoto
Hitoshi
H
Ichikawa
Kenichiro
K
Hata
Teruhiko
T
Yoshida
Kenji
K
Matsumoto
Nobutaka
N
Kiyokawa
Tetsuya
T
Mori
D002648:Child; D002875:Chromosomes / Q000648:ultrastructure; D020869:Gene Expression Profiling; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics*; D054448:Precursor Cells, B-Lymphoid / Q000166:cytology; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000737:chemistry*; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics*; D017422:Sequence Analysis, DNA; D058305:Sorting Nexins / Q000235:genetics*; D014178:Translocation, Genetic; D016896:Treatment Outcome
D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; C513979:SNX2 protein, human; D058305:Sorting Nexins; D016315:Proto-Oncogene Proteins c-abl
SNX2-ABL1; dasatinib; imatinib; precursor B-cell acute lymphoblastic leukemia; tyrosine kinase inhibitors